Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Optimising the design of phase II oncology trials: the importance of randomisation.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Optimising the design of phase II oncology trials: the importance of randomisation.
Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009 Jan; 45(2):275-80.
View in:
PubMed
subject areas
Antineoplastic Agents
Clinical Trials, Phase II as Topic
Humans
Neoplasms
Observer Variation
Random Allocation
Randomized Controlled Trials as Topic
Research Design
Sample Size
Treatment Outcome
authors with profiles
Mark J. Ratain